Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

• Published in: Therapeutic advances in neurological disorders Vol. 14; p. 17562864211039648
• Main Authors: Wiendl, Heinz, Gold, Ralf, Berger, Thomas, Derfuss, Tobias, Linker, Ralf, Mäurer, Mathias, Aktas, Orhan, Baum, Karl, Berghoff, Martin, Bittner, Stefan, Chan, Andrew, Czaplinski, Adam, Deisenhammer, Florian, Di Pauli, Franziska, Du Pasquier, Renaud, Enzinger, Christian, Fertl, Elisabeth, Gass, Achim, Gehring, Klaus, Gobbi, Claudio, Goebels, Norbert, Guger, Michael, Haghikia, Aiden, Hartung, Hans-Peter, Heidenreich, Fedor, Hoffmann, Olaf, Kallmann, Boris, Kleinschnitz, Christoph, Klotz, Luisa, Leussink, Verena I., Leutmezer, Fritz, Limmroth, Volker, Lünemann, Jan D., Lutterotti, Andreas, Meuth, Sven G., Meyding-Lamadé, Uta, Platten, Michael, Rieckmann, Peter, Schmidt, Stephan, Tumani, Hayrettin, Weber, Frank, Weber, Martin S., Zettl, Uwe K., Ziemssen, Tjalf, Zipp, Frauke
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 2021; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Central nervous system; Demyelination; Inflammation; Multiple sclerosis; Review; treatment recommendation; multiple sclerosis; disease-modifying therapy; guideline

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years h...